share_log

HC Wainwright & Co. Maintains Neutral on NovoCure, Raises Price Target to $24

Moomoo 24/7 ·  Mar 27 13:44

HC Wainwright & Co. analyst Emily Bodnar maintains NovoCure (NASDAQ:NVCR) with a Neutral and raises the price target from $22 to $24.

Disclaimer: This content is for informational and educational purposes only and does not constitute a recommendation or endorsement of any specific investment or investment strategy. Read more
    Write a comment